Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Oral Minoxidil in Adults 65 and Older: What the Evidence Says About Safety

By
Published Updated Last reviewed
6 linked public sourcesEditorial, sourcing, and corrections policy

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Key numbers

  • 15.1%Hypertrichosis, the most frequent effect in the 1,404-patient cohortSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 6.8%Systemic adverse effects among hypertension cohort patients being dose-titratedSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07
  • 2.67 beats/minHeart-rate rise with low-dose oral minoxidil (5 mg/day or less) in uncontrolled studiesSource: pubmed.ncbi.nlm.nih.gov, as cited 2026-11-07

At a glance

  • Approval / tablets are approved only for severe hypertension; hair-growth use is off-label [2]
  • Largest safety cohort / 1,404 patients, mean age 43, range 8 to 86 [1]
  • Hypertension cohort / 254 patients, mean age 56.9, range 19 to 82 [3]
  • Blood pressure at 5 mg/day or less / no significant change; heart rate up 2.67 beats/min [4]
  • Only interaction named in the oral label / guanethidine [2]

Is there safety data just for people over 65?

Older adults appear inside mixed-age cohorts rather than in a study of their own. The largest is a retrospective multicenter study of 1,404 patients treated at least 3 months, mean age 43, range 8 to 86, with no control group [1]. The closest to an older population is a 2024 retrospective study of 254 patients who already had hypertension: mean age 56.9, range 19 to 82, taking a mean of 1.45 antihypertensive drugs [3]. Both include patients in their 80s; neither reports a separate rate for patients over 65.

Questions worth asking

Choose the questions you want to keep

What the cohorts measured

In the 1,404 patients, hypertrichosis was the most frequent effect at 15.1% and led to withdrawal in 14 patients (0.5%). Lightheadedness occurred in 1.7%, fluid retention 1.3% and tachycardia 0.9%, and systemic effects led to discontinuation in 29 patients (1.2%). No life-threatening adverse effects were observed [1].

In the hypertension cohort, the dose was titrated in 128 patients, allowing analysis of 382 doses. Systemic adverse effects occurred in 26 cases (6.8%), including lightheadedness (3.1%) and fluid retention (2.6%), and led to discontinuation in 6 cases (1.5%). Prior doxazosin (P<0.001) and three or more antihypertensive drugs (P=0.012) were associated with a higher risk of discontinuation [3].

A meta-analysis of uncontrolled studies of 5 mg/day or less found no significant change in systolic pressure (mean difference -0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic pressure (-1.25, 95% CI -3.21 to 0.71), and a 2.67 beats/min rise in heart rate (95% CI 0.34 to 5.01) [4].

What the label flags

The boxed warning covers pericardial effusion, occasionally progressing to tamponade, and worsened angina, and reserves the tablets for hypertension not controlled by maximum doses of a diuretic plus two other antihypertensives [2]. The label's rates are for antihypertensive use: effusion in about 3% of treated patients not on dialysis, especially with compromised renal function; reversible edema in about 10%; ECG T-wave changes in about 60% [2]. The label also states that renal clearance corresponds to glomerular filtration rate and that the drug can be removed by hemodialysis [2]. The only interaction named in the oral label is guanethidine, which can cause profound orthostatic hypotension [2].

A 2025 international consensus statement of 43 hair-loss specialists in 12 countries reached agreement on contraindications, precautions, baseline evaluation and monitoring for low-dose oral minoxidil. Its authors list the long-term safety of low-dose oral minoxidil among the topics that need further investigation [5].

Dr Crystal Aguh on what the FDA label says about oral minoxidil

Dr Aguh explains that oral minoxidil is only FDA approved to treat high blood pressure, usually at doses between ten and forty milligrams a day. She stresses that the much lower doses used for hair loss fall outside that approved use. In her view, minoxidil for hair loss should only be considered after a diagnosis of androgenetic alopecia by a board certified dermatologist, and she encourages people to wait for that appointment rather than start on their own. The video focuses on who is a candidate and does not address safety in adults over sixty five.

Who is speaking?

Crystal Aguh, MD. Physician, as named on the channel; she describes herself as a dermatologist in the video Background

Episode notes and full video

Frequently asked questions

Is there a standard oral minoxidil dose for people over 65?
The label gives one antihypertensive schedule for everyone over 12: start at 5 mg daily, adjust at intervals of at least 3 days, usual effective range 10 to 40 mg/day [2]. Low-dose regimens for hair loss are off-label, and the label states that use of minoxidil tablets to promote hair growth is not an approved indication [2].
Does low-dose oral minoxidil change blood pressure or heart rate?
A meta-analysis of uncontrolled studies of 5 mg/day or less found no significant change in systolic or diastolic pressure and a 2.67 beats/min rise in heart rate (95% CI 0.34 to 5.01), with hypotensive symptoms in 5.0% of patients and no hypotensive episodes [4].
Can someone already taking blood pressure medicines use it?
The only interaction named in the oral label is guanethidine, which can cause profound orthostatic hypotension [2]. In the hypertension cohort, prior doxazosin (P<0.001) and three or more antihypertensive drugs (P=0.012) were associated with a higher risk of stopping treatment [3].

What people actually ask

What are the potential risks of taking minoxidil?

The most frequent effect in the largest cohort was hypertrichosis, reported in 15.1% of 1,404 patients and leading to withdrawal in 14 (0.5%). Lightheadedness occurred in 1.7%, fluid retention in 1.3% and tachycardia in 0.9%, and no life-threatening adverse effects were observed. The boxed warning covers pericardial effusion, occasionally progressing to tamponade, and worsened angina, with rates reported for antihypertensive use.

Can a 70 year old use minoxidil?

The available evidence does not establish this. No cohort reports results for adults 65 and older as a separate group. The largest cohort had a mean age of 43 and a range of 8 to 86, and the hypertension cohort ranged from 19 to 82, so both include people in their 80s without a separate rate for patients over 65.

Is minoxidil FDA approved?

No, not for hair loss. The tablets are approved only for severe hypertension, and the label states that using minoxidil tablets to promote hair growth is not an approved indication. Hair-growth use is off-label.

References

  1. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
  2. U.S. National Library of Medicine, DailyMed. Minoxidil tablets (oral), Actavis Pharma prescribing information. Minoxidil tablets (oral) label
  3. Jimenez-Cauhe J, Pirmez R, Müller-Ramos P, Melo DF, Ortega-Quijano D, Moreno-Arrones OM, et al. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients. Actas Dermosifiliogr. 2024;115(1):28-35. Safety of Low-Dose Oral Minoxidil in Patients With Hypertension and Arrhythmia: A Multicenter Study of 264 Patients
  4. Chen M, Weichert M, Guo W, Ruzic R, Briley J. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(3):554-555. Low-dose oral minoxidil does not significantly affect blood pressure: A systematic review and meta-analysis
  5. Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, et al. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement. JAMA Dermatol. 2025;161(1):87-95. Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement
  6. Crystal Aguh, MD. What You Need to Know About Oral Minoxidil. Accessed 2026-11-11.
Evidence overview for Oral Minoxidil in Adults 65 and Older: What the Evidence Says About Safety